Authors
Yan Chen, Boyun Yang, Wo Yao, Ran Diao, Yongfang Wang, Bohui Li, Ting Li, Liuya Ge, Yingying Hu, Huiying Wang
Published in
Frontiers in medicine. Volume 13. Pages 1964856. Epub Oct 20, 2026.
Abstract
Direct real-world comparisons of omalizumab (OMA) and dupilumab (DUP) for moderate-to-severe asthma remain limited. We compared clinical and biomarker changes during treatment with these biologics.
This retrospective, single-center, real-world cohort included 72 adults who initiated OMA (n = 48) or DUP (n = 24) between January 2024 and December 2025 and continued treatment through approximately 4 months. Outcomes were assessed at baseline and approximately 4 and 12 months. Exploratory analyses compared four-month changes between groups, and available repeated measurements were evaluated using adjusted linear mixed-effects models.
Both OMA and DUP treatments were associated with improved asthma control and pulmonary function at 4 months, with no clear between-group differences in changes in Asthma Control Test (ACT) score, blood eosinophil count, fractional exhaled nitric oxide, or pulmonary function parameters. Adjusted models showed improvements over time in ACT score (P < 0.001) and percent-predicted forced expiratory volume in one second (P = 0.002), without significant treatment-group effects or treatment-by-time interactions. Serum total immunoglobulin E (IgE) increased with OMA and decreased with DUP at 4 months, with a significant four-month treatment-by-time interaction (P < 0.001) in the longitudinal model.
In this cohort, OMA and DUP were each associated with improvements in asthma control and pulmonary function, with no clear between-group differences detected. Their differing 4-month changes in serum total IgE were consistent with differences in their pharmacodynamic effects.
PMID:
42978889
Bibliographic data and abstract were imported from PubMed on 04 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 73
- Comments 0